Hot COVID-19
Home > News > CEO Dr. Johnson Lau of Athenex, Inc Contracts COVID-19
Industry Updates New Products Supplier News Upcoming Events business web

CEO Dr. Johnson Lau of Athenex, Inc Contracts COVID-19

Hits:260   Date: 1/11/2021
BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr. Johnson Lau, has contracted COVID-19. Dr. Lau is receiving oral and intravenous treatment at a local hospital, and his condition is currently stable. Dr. Lau is communicating with senior management and continues to serve as Athenex’s CEO. Under the advice of his physician, he will not be able to attend the 39th Annual J.P. Morgan Healthcare Conference. Athenex’s senior management team will continue to participate and present at the 39th Annual J.P. Morgan Healthcare Conference at its previously scheduled presentation time, and investor one-on-one meetings.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina. For more information, please visit
Steve Rubis
Athenex, Inc.
Daniel Lang, MD
Athenex, Inc.
Tim McCarthy
LifeSci Advisors, LLC